82 results
8-K
EX-99.1
WINT
Windtree Therapeutics Inc
15 Mar 22
Windtree Completes Enrollment of Phase 2 Study of Istaroxime in Early Cardiogenic Shock
7:04am
the global pandemic,” said Steve Simonson, MD, CMO of Windtree Therapeutics.
Cardiogenic shock is a serious condition that occurs when the heart … of such risks and uncertainties include: risks and uncertainties associated with the ongoing economic and social consequences of the COVID-19 pandemic
8-K
EX-99.1
WINT
Windtree Therapeutics Inc
29 Mar 21
Windtree Therapeutics Reports Fourth Quarter and Year End 2020 Financial Results and Provides Key Business Updates
5:26pm
2a and 2b studies in the fundamental initiative of progressing it as a new therapy in acute heart failure. Additionally, given the pandemic, we saw … : risks and uncertainties associated with the ongoing economic and social consequences of the COVID-19 pandemic, including any adverse impact
8-K
EX-99.1
hqq78glotx2m172r sbd
3 Apr 20
Windtree Therapeutics Reports Fourth Quarter 2019 Financial Results and Provides Key Business Updates
6:31am
8-K
EX-99.1
hos rm89m
3 Aug 09
Discovery Labs Provides Second Quarter 2009 Financial Results and Business Strategy Update
12:00am
8-K
EX-99.1
iu2yp6
5 Dec 22
Other Events
7:48am
8-K
EX-99.1
zo0g3dej
29 Apr 20
Windtree Therapeutics Announces Reverse Stock Split
5:29pm
8-K
EX-99.1
la5reiz k8
22 May 20
Windtree Therapeutics Announces Pricing of $20.0 Million Public Offering and Uplisting to the Nasdaq Capital Market
5:22pm
8-K
EX-99.1
3zx4gq98wabd2b
31 Jan 24
Windtree Therapeutics Announces Engagement of Strategic Advisor to Support Assessment of Strategic Alternatives
8:00am
8-K
EX-99.1
dnjzflqd2xc
1 Oct 20
Windtree Announces First Patient Dosed in Phase 2 Study of Istaroxime for the Acute Treatment of Early Cardiogenic Shock in Heart Failure Patients
7:36am
8-K
EX-99.2
u56oom h78onefrfkx
22 May 20
Windtree Therapeutics Announces Pricing of $20.0 Million Public Offering and Uplisting to the Nasdaq Capital Market
5:22pm